“Pelago has established itself as a unique and highly reliable technology and service provider in the discovery of novel therapeutics, with significant growth runway for the Company’s existing platform centered around its patented CETSA^® technology for target engagement assessment. Impilo is excited to partner with the Founders and support the management team of Pelago in driving market penetration and a customer focused platform expansion with an attractive scope to broaden the service portfolio, organically as well as through M&A, and thus assist customers through several phases of the drug discovery process.”

“Impilo is the ideal partner for Pelago as we continue on our mission to enable better drug discovery for our customers. As a long-term and dedicated healthcare and life science investor, with vast experience from the pharma services sector, Impilo will contribute important competence for the next phase of our growth journey. Through the partnership we will be able to further invest and build our capacity and competence to accelerate business development initiatives and expand the applicability of our CETSA^® technology for the benefit of our existing and new customers. We as Founders, together with the entire Pelago team, look forward to this next exciting phase in the development of the Company.”